RNF115/BCA2 E3 ubiquitin ligase promotes breast cancer cell proliferation through targeting p21Waf1/Cip1 for ubiquitin-mediated degradation

Neoplasia (United States)

Volumn 15, Issue 9, 2013, Pages 1028-1035

  Wang, Zehua ^a   Nie, Zhi ^b   Chen, Wenlin ^b   Zhou, Zhongmei ^a   Kong, Qinghua ^a   Seth, Arun K ^c   Liu, Rong ^a,d   Chen, Ceshi ^a  

^a KUNMING INSTITUTE OF ZOOLOGY   (China)

^b KUNMING MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF TORONTO   (Canada)

^d University of Toronto ^*  (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1A; PROTEIN P21; SMALL INTERFERING RNA; UBIQUITIN PROTEIN LIGASE E3;

ARTICLE; BREAST CANCER; BREAST CANCER ASSOCIATED GENE 2; CELL CYCLE PROGRESSION; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; GENE; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN STABILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UBIQUITINATION; UPREGULATION; WESTERN BLOTTING;

BREAST NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; ESTROGEN RECEPTOR ALPHA; FEMALE; HEK293 CELLS; HUMANS; MCF-7 CELLS; RNA INTERFERENCE; RNA, SMALL INTERFERING; UBIQUITIN; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 84884381774     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.13678     Document Type: Article

References (24)

1. Carrano AC, Eytan E, Hershko A, and Pagano M (1999). SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1, 193-199.
2. CIP1/WAF1 and cyclin D proteins. Proc Natl Acad Sci USA 95, 11324-11329.
3. Fbw7 ubiquitin ligase. Science 294, 173-177.
4. Strohmaier H, Spruck CH, Kaiser P, Won KA, Sangfelt O, and Reed SI (2001). Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature 413, 316-322.
5. Yada M, Hatakeyama S, Kamura T, Nishiyama M, Tsunematsu R, Imaki H, Ishida N, Okumura F, Nakayama K, and Nakayama KI (2004). Phosphorylationdependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J 23, 2116-2125.
6. Welcker M, Orian A, Jin J, Grim JE, Harper JW, Eisenman RN, and Clurman BE (2004). The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc Natl Acad Sci USA 101, 9085-9090.
7. Zhao D, Zheng HQ, Zhou Z, and Chen C (2010). The Fbw7 tumor suppressor targets KLF5 for ubiquitin-mediated degradation and suppresses breast cell proliferation. Cancer Res 70, 4728-4738.
8. Burger AM, Gao Y, Amemiya Y, Kahn HJ, Kitching R, Yang Y, Sun P, Narod SA, Hanna WM, and Seth AK (2005). A novel RING-type ubiquitin ligase breast cancer-associated gene 2 correlates with outcome in invasive breast cancer. Cancer Res 65, 10401-10412.
9. Kona FR, Stark K, Bisoski L, Buac D, Cui Q, and Dou QP (2012). Transcriptional activation of breast cancer-associated gene 2 by estrogen receptor. Breast Cancer Res Treat 135, 495-503.
10. Amemiya Y, Azmi P, and Seth A (2008). Autoubiquitination of BCA2 RING E3 ligase regulates its own stability and affects cell migration. Mol Cancer Res 6, 1385-1396.
11. Miyakawa K, Ryo A, Murakami T, Ohba K, Yamaoka S, Fukuda M, Guatelli J, and Yamamoto N (2009). BCA2/Rabring7 promotes tetherin-dependent HIV-1 restriction. PLoS Pathog 5, e1000700.
12. Bacopulos S, Amemiya Y, Yang W, Zubovits J, Burger A, Yaffe M, and Seth AK (2012). Effects of partner proteins on BCA2 RING ligase activity. BMC Cancer 12, 63.
13. Denicourt C and Dowdy SF (2004). Cip/Kip proteins: more than just CDKs inhibitors. Genes Dev 18, 851-855.
14. Gartel AL and Radhakrishnan SK (2005). Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res 65, 3980-3985.
15. Rowland BD and Peeper DS (2006). KLF4, p21 and context-dependent opposing forces in cancer. Nat Rev Cancer 6, 11-23.
16. Cdt2 ubiquitin ligase complex. Genes Dev 22, 2496-2506.
17. Cdc20 controls the ubiquitin-mediated degradation of p21 in prometaphase. Mol Cell 27, 462-473.
18. Lee EW, Lee MS, Camus S, Ghim J, Yang MR, Oh W, Ha NC, Lane DP, and Song J (2009). Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell cycle arrest and apoptosis. EMBO J 28, 2100-2113.
19. Zhi X, Zhao D, Wang Z, Zhou Z, Wang C, Chen W, Liu R, and Chen C (2013). E3 ubiquitin ligase RNF126 promotes cancer cell proliferation by targeting the tumor suppressor p21 for ubiquitin-mediated degradation. Cancer Res 73, 385-394.
20. Burger A, Amemiya Y, Kitching R, and Seth AK (2006). Novel RING E3 ubiquitin ligases in breast cancer. Neoplasia 8, 689-695.
21. Xu S, Feng Z, Zhang M, Wu Y, Sang Y, Xu H, Lv X, Hu K, Cao J, Zhang R, et al. (2011). hSSB1 binds and protects p21 from ubiquitin-mediated degradation and positively correlates with p21 in human hepatocellular carcinomas. Oncogene 30, 2219-2229.
22. Chen C, Zhou Z, Guo P, and Dong JT (2007). Proteasomal degradation of the KLF5 transcription factor through a ubiquitin-independent pathway. FEBS Lett 581, 1124-1130.
23. Kip2 CDK inhibitors. Cell Cycle 9, 2342-2352.
24. Nakayama KI and Nakayama K (2006). Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 6, 369-381.